"Overall, we found that Prostate Health Index above 55 preoperatively was associated with any incidental prostate cancer as well as clinically significant prostate cancer," says Eric Li, MD.
In this video, Eric Li, MD, highlights findings from his study, “Prostate Health Index is associated with Incidental Prostate Cancer Detection at Time of Holmium Laser Enucleation of the Prostate,” which will be presented at the 2023 Annual American Urological Association Conference in Chicago, Illinois. Li is a urology resident at Northwestern University Feinberg School of Medicine in Chicago, Illinois.
Video Transcript:
These are patients who had prostate cancer found at the time of holmium enucleation of the prostate, which is a procedure done on the prostate to help men urinate better. Historically, rates of cancer detection had been as high as 20%. Now we have these advanced screening tools such as Prostate Health Index and prostate MRI. The question is, what are the new preoperative risk factors for finding prostate cancer at the time of HoLEP, or holmium enucleation of the prostate. The reason why this is relevant is because if we detect clinically significant prostate cancer preoperatively these patients may actually benefit from radical prostatectomy rather than a HoLEP. Overall, we found that Prostate Health Index above 55 preoperatively was associated with any incidental prostate cancer as well as clinically significant prostate cancer. The takeaway is that these patients should undergo biopsy to make sure that they don't have cancer that would require other treatment before going HoLEP.
This transcription has been edited for clarity.
Lenvatinib plus pembrolizumab delays all organ tumor progression in advanced RCC
June 7th 2024“Overall, our results continue to support the use of lenvatinib and pembrolizumab as a current standard treatment option in the first-line treatment of [patients with] kidney cancer," says Viktor Grünwald, MD, PhD.
Pembrolizumab plus platinum-based therapy shows safety, efficacy in penile cancer
June 4th 2024“The HERCULES trial is the first trial to demonstrate the efficacy of immune checkpoint inhibitors in [patients with] advanced penile cancer with [a] manageable safety profile," says Fernando Cotait Maluf, MD.